Biobiggen
Daxing
About Biobiggen
Biobiggen is a non-invasive prenatal chromosomal disease and monogenic disease simultaneous screening technology platform. It is focusing on the pregnancy and childbirth period, focusing on prenatal screening, supplemented by newborn screening and prenatal diagnosis, and deeply creating the most complete high-throughput prevention and control of genetic diseases and birth defects Sequencing technology series of innovative products, leading enterprises and unicorn enterprises in the subdivision field. The company is headquartered in Beijing Economic and Technological Development Zone, has an overseas research center in Houston, the United States, and an R&D transformation center, GMP production base, and medical testing laboratory in Beijing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Funding stage: Seed
- Last round: Seed (Jan 2021)
- Website: biobiggen.com
- Phone: 010-87163180
Industries & Categories
Genetics, Health Care, Health Diagnostics, Medical
Canonical: https://fsome.com/organization/biobiggen-2774459 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.